Skip to main content
. 2025 Aug 12;12:1575580. doi: 10.3389/fnut.2025.1575580

Table 2.

Characteristics of studies.

Author and year Country Study design Groups (sample size) Age (sex) Definition of sarcopenic obesity Assessment tool of body composition Type of exercise intervention Time point of measurement Outcomes
Sarcopenia Obesity
Balachandran
2014 (26)
America Parallel-group RCT Hypertrophy (9) 71 ± 8.2 (F) SMI < 10.76 kg/m2 in men and 6.76 kg/m2 in women or gait speed <1 m/s or GS < 30 kg for men and 20 kg for women BMI > 30 kg/m2 BIA RT Baseline: 0 week
Posttest: 15th week
SPPB, leg press power, 1-RM of leg press and chest press, BF%, LBM, SMI; PFP-10, GS
High-speed circuit (8) 71.6 ± 7.8 (Both)
Kim
2016 (28)
Japan Parallel-group RCT Exercise (35) 81.4 ± 4.31 (F) SMI < 5.67 kg/m2 or GS < 17 kg or WS < l m/s BF% > 32 BIA Combined exercise Baseline: 0 week
Posttest: 12th week
BF%, TFM, ASM, GS, KES, WS; TC, TG; IL-6, hs-CRP
Health Education (34) 81.1 ± 5.11 (F) Non-exercise
Maltais
2016 (27)
America Parallel-group RCT RT + Nondairy Shake (8) 64 ± 4.9 (M) SMI < 10.75 kg/m2 BMI > 30 kg/m2 DXA RT Baseline: 0 week
Posttest: 16th week
BMI, FM; TG, HDL, LDL, TC, GLU, insulin; IL-6, TNF-α, CRP
RT + Dairy Shake (8) 68 ± 5.1 (M)
RT (10) 64 ± 4.5 (M)
Vasconcelos 2016 (29) Brazil Parallel-group RCT Exercise (14) 72 ± 4.61 (F) handgrip strength ≤21 kg BMI ≥ 30 kg/m2 NA RT Baseline: 0 week
Posttest: 10th week
strength, power, SPPB, gait velocity, SF-36
Control (14) 72 ± 3.61 (F) Non-exercise
Chen
2017 (31)
China Parallel-group RCT RT (15) 68.9 ± 4.4 (Both) SMI < 32.5%in men, <25.7% in women BMI ≥ 25 kg/m2 and VFA ≥ 100 cm2 BIA RT Baseline: 0 week
Posttest: 8th week
BMI, PBF%, SMM, ASM/Weight; Grip, BES; IGF-1
AR (15) 69.3 ± 3.0 (Both) AR
Combination training (15) 68.5 ± 2.7 (Both) Combined exercise
Control (15) 68.6 ± 3.1 (Both) Non-exercise
Huang
2017 (32)
China Parallel-group RCT ERT (18) 68.89 ± 4.91 (F) SMI < 27.6% BF% > 30 DXA RT Baseline: 0 week
Posttest: 12th week
BMI, SMI, BF%, TFM; T-score, Z-score; TG, HDL, LDL, TC; CRP
Control (17) 69.53 ± 5.09 (F) Non-exercise
Liao
2017 (24)
China Parallel-group RCT Experimental (25) 66.39 ± 4.491 (F) SMI < 7.15 kg/m2 BF% > 30 DXA RT Baseline: 0 week
Posttest: 12th week
FFM, LLM, TFM, BF%; GS, TUG, handgrip
Control (21) 68.42 ± 5.86 1 (F) Non-exercise
Park
2017 (33)
Korea Parallel-group RCT Combined exercise (25) 73.5 ± 7.11 (F) ASM/ weight <25.1% BMI ≥ 25.0 kg/m2 DXA Combined exercise Baseline: 0 week
Posttest: 24th week
BF%, ASM; GS, sit and reach, MWS; TG, HDL, LDL, TC; hs-CRP
Control (25) 74.7 ± 5.11 (F) Non-exercise
Chiu
2018 (39)
China Parallel-group RCT Exercise (33) 79.64 ± 7.36 (Both) SMI (TSM/BW) < 37.15% in men; <32.26% in women BF% > 29 in men; BF% > 40 in women BIA RT Baseline: 0 week
Posttest: 12th week
skeletal muscle%, ASMI, BF%; GS, total pinch strength, total FIM score
Comparison (31) 80.15 ± 8.26 (Both) Non-exercise
Liao
2018 (37)
China Parallel-group RCT Experimental (33) 66.67 ± 4.541 (F) SMI < 27.6% BF% > 30 BIA RT Baseline: 0 week
Posttest: 12th week
BF%, TSM, ALM, LMI, AMI, SMI %; GS, TUG, UE, LE, SF-36
Control (23) 68.32 ± 6.051 (F) Non-exercise
Nabuco
2019 (30)
Brazil Parallel-group RCT RT + whey protein (13) 68.0 ± 4.21 (F) ASM < 15.02 kg BF% > 35 DXA RT Baseline: 0 week
Posttest: 12th week
ALST, WC, TFM; 10 MW, KES, chest press; TG, HDL, LDL, TC, GLU, insulin, HOMA-IR; IL-6, TNF-α, CRP
RT (13) 70.1 ± 3.91 (F)
Liao
2020 (38)
China Parallel-group RCT Experimental (20) 72.22 ± 7.751 (F) gait speed <0.8 m/s BMI
≥ 24 kg/m2
DXA RT Baseline: 0 week
Posttest: 12th week
arm lean mass, leg lean mass, ASMI, gait speed, WOMAC−PF, UE, LE
Control (20) 69.79 ± 6.721 (F) Non-exercise
Jung
2022 (34)
Korea Parallel-group RCT Exercise (14) 75.36 ± 4.501 (F) ASM/height ≤5.4 kg/m2 BF% > 32 DXA Circuit exercise Baseline: 0 week
Posttest: 12th week
BMI, FFM, ASMI, WHR; TG, HDL, LDL, TC, HOMA-IR
Control (14) 74.64 ± 5.771 (F) Non-exercise
Magtouf
2023 (36)
Tunisia Parallel-group RCT Exercise (25) 76.1 ± 3.5 (NA) handgrip <17 N, gait speed <1.0 m/s BMI
≥ 30 kg/m2
NA Concurrent Exercise Baseline: 0 week
Posttest: 24th week
BMI, BF%, FBM, LBM, WC, HC; hand grip, GS, TUG, Romberg test
Control (25) 75.9 ± 5.4 (NA) Non-exercise
Jung
2024 (35)
Korea Parallel-group RCT Exercise (14) 78.14 ± 3.721 (F) ASM/height ≤5.4 kg/m2 BF% > 32 BIA, DXA Circuit Exercise Baseline: 0 week
Posttest: 12th week
BMI, FFM, BF%, ASMI; hs-CRP, IL-6, TNF-α
Control (14) 78.21 ± 3.721 (F) Non-exercise

RCT, randomized controlled trial; ERT, elastic band resistance training; RT, resistance training; F, female; M, male; SMI, skeletal muscle index; BMI, body mass index; BF%, body fat percentage; DXA, dual-energy X-ray absorptiometry; BIA, bioelectrical impedance analysis; ASM, appendicular muscle mass; FM, fat mass; FFM, fat-free mass; TFM, total fat mass; ALST, appendicular lean soft tissue; TSM, total skeletal muscle; WC, waist circumference; 10 MW, 10 m walk test; KES, knee extensor strength; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; GLU, glucose; IL-6, interleukin-6; IL-8, interleukin-8; CRP, C-reactive protein; TNF-α, tumor necrosis factor alpha; IGF-1, insulin-like growth factor-1; HOMA-IR, homeostatic model assessment of insulin resistance; ASMI, appendicular skeletal muscle mass index; WHR, waist-to-hip ratio; GS, grip strength; MWS, maximum walking speed; WS, walking speed; SPPB, short physical performance battery; SF-36, 36-item Short Form Health Survey; SM, skeletal muscle mass; ALM, appendicular lean mass; LMI, lean mass index; TUG, timed up and go; UE, upper extremity; LE, lower extremity; WOMAC-PF, physical function subscale of Western Ontario & McMaster Universities Osteoarthritis Index; HC, hip circumference; 1-RM, one-repetition maximum; LBM, lean body mass; PFP-10, physical functional performance test; NA, not available.